Viridian Therapeutics, Inc. (VRDN)
22.20
+0.96
(+4.52%)
USD |
NASDAQ |
Sep 14, 16:00
21.89
-0.31
(-1.40%)
After-Hours: 20:00
Viridian Therapeutics Price to Book Value : 4.457 for Sept. 14, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| September 14, 2026 | 4.457 |
| September 11, 2026 | 4.264 |
| September 10, 2026 | 4.475 |
| September 09, 2026 | 4.563 |
| September 08, 2026 | 4.651 |
| September 04, 2026 | 4.601 |
| September 03, 2026 | 4.609 |
| September 02, 2026 | 4.573 |
| September 01, 2026 | 4.623 |
| August 31, 2026 | 4.649 |
| August 28, 2026 | 4.633 |
| August 27, 2026 | 4.794 |
| August 26, 2026 | 4.870 |
| August 25, 2026 | 4.854 |
| August 24, 2026 | 4.822 |
| August 21, 2026 | 4.876 |
| August 20, 2026 | 4.918 |
| August 19, 2026 | 4.979 |
| August 18, 2026 | 4.804 |
| August 17, 2026 | 4.635 |
| August 14, 2026 | 4.433 |
| August 13, 2026 | 4.414 |
| August 12, 2026 | 4.593 |
| August 11, 2026 | 4.611 |
| August 10, 2026 | 4.629 |
| Date | Value |
|---|---|
| August 07, 2026 | 4.736 |
| August 06, 2026 | 4.519 |
| August 05, 2026 | 4.230 |
| August 04, 2026 | 4.184 |
| August 03, 2026 | 3.876 |
| July 31, 2026 | 3.798 |
| July 30, 2026 | 3.995 |
| July 29, 2026 | 3.991 |
| July 28, 2026 | 3.917 |
| July 27, 2026 | 3.955 |
| July 24, 2026 | 3.868 |
| July 23, 2026 | 3.866 |
| July 22, 2026 | 3.848 |
| July 21, 2026 | 3.850 |
| July 20, 2026 | 3.726 |
| July 17, 2026 | 3.620 |
| July 16, 2026 | 3.620 |
| July 15, 2026 | 3.826 |
| July 14, 2026 | 3.830 |
| July 13, 2026 | 3.812 |
| July 10, 2026 | 3.963 |
| July 09, 2026 | 4.055 |
| July 08, 2026 | 3.987 |
| July 07, 2026 | 4.109 |
| July 06, 2026 | 3.812 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.626 |
| Alnylam Pharmaceuticals, Inc. | 24.69 |
| Anika Therapeutics, Inc. | 2.066 |
| Savara, Inc. | 7.635 |
| Vericel Corp. | 5.476 |
Price to Book Value Related Metrics
| PS Ratio | 30.14 |
| Price | 22.20 |
| Earnings Yield | -16.70% |
| Market Cap | 2.514B |